VERAHIGH SIGNALFINANCIAL10-K

VERA shows substantially deteriorating financial performance with net losses roughly doubling and a significant increase in R&D spending, while removing previous going concern language despite the worsening metrics.

The company appears to be in an intensive development phase with meaningfully expanded R&D investments, but this comes at the cost of substantially higher cash burn and operating losses. The removal of going concern language and more generic risk factor descriptions suggests management may have improved confidence in funding runway, though the financial trajectory indicates accelerated cash consumption.

Comparing 2026-02-26 vs 2025-02-28View on EDGAR →
FINANCIAL ANALYSIS

VERA's financial position reflects a company in heavy investment mode, with R&D expenses growing substantially and operating losses roughly doubling year-over-year. Operating cash flow deteriorated meaningfully while total assets grew modestly and total liabilities increased substantially. The company maintains a strong balance sheet with current assets of $729M, but the dramatically higher burn rate suggests this capital will be consumed much more rapidly than in the prior period.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
-96.9%
-$152.1M→-$299.6M

Net income declined 96.9% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-88.7%
-$167.2M→-$315.5M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Operating Cash Flow
Cash Flow
-79%
-$134.7M→-$241.1M

Operating cash flow fell 79% — earnings quality concerns; investigate working capital changes and non-cash items.

R&D Expense
P&L
+70.6%
$126.2M→$215.3M

R&D investment increased 70.6% — signals commitment to future product development, though near-term margin impact.

Total Liabilities
Balance Sheet
+65.8%
$78.5M→$130.2M

Liabilities grew 65.8% — significant increase in debt or obligations, assess impact on financial flexibility.

Total Debt
Balance Sheet
+47.6%
$50.7M→$74.8M

Debt increased 47.6% — substantial leverage increase; assess whether deployed for growth or covering losses.

Capital Expenditure
Cash Flow
-35.2%
$972K→$630K

Capex reduced 35.2% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Total Assets
Balance Sheet
+12.1%
$655.7M→$734.7M

Asset base grew 12.1% — expansion through organic growth, acquisitions, or capital deployment.

Current Assets
Balance Sheet
+11.9%
$651.2M→$728.9M

Current assets grew 11.9% — improving short-term liquidity or inventory/receivables build.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-28
ADDED
As of February 23, 2026 , the registra nt had 71,355,667 shares of Class A common stock, $0.001 par value per share, and no shares of Class B common stock, $0.001 par value per share, outstanding.
We have incurred net losses since inception, and have never generated revenue from product sales.
We expect to continue to incur net losses at least until we have one or more approved products that achieve commercial success.
We are substantially dependent on the success of our product candidates.
If the market opportunities for our product candidates, if and when approved, are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability might be materially and adversely affected.
Disruptions at the FDA and other government agencies caused by funding shortages, staffing limitations, or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, and prevent new or modified products from being developed, reviewed, approved or commercialized in a timely manner or at all, which could negatively impact our business.
Unfavorable geopolitical and global economic conditions, including tariffs and trade tensions, could adversely affect our business, financial condition and results of operations.
Our success is highly dependent on our ability to attract and retain highly skilled executive officers, employees and key consultants.
If we breach our license agreement with Ares Trading S.A., an affiliate of Merck KGaA, Darmstadt, Germany, related to atacicept, the license agreement with Novartis International Pharmaceutical AG related to MAU868, or the license agreement with the Board of Trustees of Leland Stanford Junior University related to VT-109, we could lose the ability to continue the development and commercialization of atacicept, MAU868, or VT-109, respectively.
We may be required to make significant payments under our license agreements related to our product candidates.
REMOVED
As of February 24, 2025 , the registra nt had 63,748,290 shares of Class A common stock, $0.001 par value per share, and no shares of Class B common stock, $0.001 par value per share, outstanding.
We have incurred net losses since inception, and we expect to continue to incur net losses for the foreseeable future.
In addition, we may be unable to continue as a going concern over the long-term.
We are substantially dependent on the success of our product candidates, atacicept and MAU868, which are currently in the clinical development stage, and VT-109, which is in the pre-clinical development stage.
If the market opportunities for atacicept, MAU868, VT-109, or any future product candidate we may develop, if and when approved, are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability might be materially and adversely affected.
Unfavorable geopolitical and global economic conditions could adversely affect our business, financial condition and results of operations.
iv Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees and key consultants.
If we breach our license agreement (Ares Agreement) with Ares Trading S.A.
(Ares), an affiliate of Merck KGaA, Darmstadt, Germany, related to atacicept, or the license agreement with Novartis International Pharmaceutical AG (Novartis) related to MAU868, or the license agreement with the Board of Trustees of Leland Stanford Junior University (Stanford) related to VT-109, we could lose the ability to continue the development and commercialization of atacicept, MAU868, or VT-109, respectively.
We may be required to make significant payments under our license agreements related to atacicept, MAU868, and VT-109.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →